Λίστα αντικειμένων
In cases of relapse after allo-HCT, up to 50% of patients have
cytogenetic or molecular evolution of their disease [15].A
recent analysis in patients with MDS suggested that relapse
after allo-HCT is driven by subclones evolving from founding
clones existing before allo-HCT but harboring new aberrations
[11], arguing for clonal evolution. Thus, a complete workup
similar to that performed at initial diagnosis is recommended
to allow detection of potentially new targetable aberrations.
Ertz-Archambault N, Kosiorek H, Slack JL, et al. Cytogenetic evolution
in myeloid neoplasms at relapse after allogeneic hematopoietic cell
transplantation: association with previous chemotherapy and effect on
survival. Biol Blood Marrow Transplant. 2017;23:782–789.
Jacoby MA, Duncavage EJ, Chang GS, et al. Subclones dominate at MDS
progression following allogeneic hematopoietic cell transplant. JCI
Insight. 2018;3:98962.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou